Scalper1 News
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals (JAZZ) got a downgrade and several price-target cuts after its lead drug, Xyrem, declined sequentially for the first time ever, leading to a quarterly miss. Sales rose 11% over the year-earlier quarter to Scalper1 News
Scalper1 News